AbbVie (ABBV) Projected to Post Earnings on Friday

by · The Cerbat Gem

AbbVie (NYSE:ABBV – Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Friday, April 25th. Analysts expect AbbVie to post earnings of $2.51 per share and revenue of $12.91 billion for the quarter. AbbVie has set its FY 2025 guidance at 12.120-12.320 EPS.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period last year, the business posted $2.79 EPS. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

AbbVie Stock Up 2.0 %

NYSE ABBV opened at $177.28 on Thursday. The business’s fifty day simple moving average is $197.30 and its 200-day simple moving average is $187.37. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The firm has a market cap of $313.60 billion, a PE ratio of 73.87, a P/E/G ratio of 1.62 and a beta of 0.55. AbbVie has a 52 week low of $153.58 and a 52 week high of $218.66.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.70%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 273.33%.

Insider Buying and Selling

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the firm’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now owns 53,234 shares of the company’s stock, valued at approximately $11,183,398.72. This trade represents a 52.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 5,778 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the transaction, the executive vice president now directly owns 22,381 shares of the company’s stock, valued at $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,471 shares of company stock worth $23,426,451 over the last 90 days. 0.25% of the stock is owned by insiders.

Institutional Trading of AbbVie

An institutional investor recently raised its position in AbbVie stock. Revolve Wealth Partners LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 72.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,279 shares of the company’s stock after acquiring an additional 3,064 shares during the quarter. Revolve Wealth Partners LLC’s holdings in AbbVie were worth $1,294,000 at the end of the most recent quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ABBV shares. Cantor Fitzgerald initiated coverage on shares of AbbVie in a report on Tuesday. They set an “overweight” rating and a $210.00 price target for the company. UBS Group raised their target price on AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Truist Financial upped their price target on AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. StockNews.com cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Wednesday, April 9th. Finally, Guggenheim restated a “buy” rating and issued a $214.00 price objective on shares of AbbVie in a report on Thursday, April 17th. Seven equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $211.19.

Get Our Latest Stock Report on AbbVie

AbbVie Company Profile

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Recommended Stories